









Markets
/
Stocks
/
nasdaq-eq
/

Equillium Inc

1.260USD

-0.180-12.50%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

45.01MMarket Cap

LossP/E TTM



Equillium Inc

1.260

-0.180-12.50%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Equillium Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Equillium Inc's Score

Industry at a Glance

Industry Ranking

135 / 407

Overall Ranking

268 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

2.500

Target Price

+73.61%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Equillium Inc Highlights

StrengthsRisks

Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 160.77% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 41.09M.

Fairly Valued

The company’s latest PE is -2.22, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.11M shares, decreasing 17.11% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 274.10K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 10.51.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.40, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 1326.28%.

Score

Industry at a Glance

Previous score

7.40

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.38

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.24

Key Metrics

Free cash flow

No Data

Equillium Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.92, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -2.22, which is -86.35% below the recent high of -0.30 and -376.47% above the recent low of -10.58.

Score

Industry at a Glance

Previous score

6.92

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 135/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Equillium Inc is 2.50, with a high of 4.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

2.500

Target Price

+73.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Equillium Inc

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.86, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 1.50 and the support level at 1.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.95

Change

-2.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.009

Neutral

RSI(14)

42.748

Neutral

STOCH(KDJ)(9,3,3)

33.689

Sell

ATR(14)

0.137

Low Volatility

CCI(14)

-117.719

Sell

Williams %R

82.051

Oversold

TRIX(12,20)

-0.167

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

1.416

Sell

MA10

1.391

Sell

MA20

1.365

Sell

MA50

1.522

Sell

MA100

1.070

Buy

MA200

0.824

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 11.62%, representing a quarter-over-quarter decrease of 79.17%. The largest institutional shareholder is The Vanguard, holding a total of 824.09K shares, representing 1.35% of shares outstanding, with 43.35% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Decheng Capital LLC

4.45M

Steel (Bruce D)

3.71M

Bradbury (Daniel M)

3.71M

Biocon SA

2.32M

Takeda Pharmaceutical Co Ltd

1.82M

Connelly (Stephen)

993.00K

The Vanguard Group, Inc.

Star Investors

824.09K

-2.12%

Cota Capital Management, LLC

562.28K

Renaissance Technologies LLC

Star Investors

274.10K

+1.71%

Geode Capital Management, L.L.C.

196.09K

-4.52%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.14, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 1.88. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.